Prospects for gene-engineered T cell immunotherapy for solid cancers

Christopher A. Klebanoff, Steven A. Rosenberg, Nicholas P. Restifo

Research output: Contribution to journalReview article

Abstract

Adoptive transfer of receptor-engineered T cells has produced impressive results in treating patients with B cell leukemias and lymphomas. This success has captured public imagination and driven academic and industrial researchers to develop similar 'off-the-shelf' receptors targeting shared antigens on epithelial cancers, the leading cause of cancer-related deaths. However, the successful treatment of large numbers of people with solid cancers using this strategy is unlikely to be straightforward. Receptor-engineered T cells have the potential to cause lethal toxicity from on-target recognition of normal tissues, and there is a paucity of truly tumor-specific antigens shared across tumor types. Here we offer our perspective on how expanding the use of genetically redirected T cells to treat the majority of patients with solid cancers will require major technical, manufacturing and regulatory innovations centered around the development of autologous gene therapies targeting private somatic mutations.

Original languageEnglish (US)
Pages (from-to)26-36
Number of pages11
JournalNature medicine
Volume22
Issue number1
DOIs
StatePublished - Jan 6 2016

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Prospects for gene-engineered T cell immunotherapy for solid cancers'. Together they form a unique fingerprint.

  • Cite this

    Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016). Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature medicine, 22(1), 26-36. https://doi.org/10.1038/nm.4015